Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Posted Flat Q3 Revenue as R&D Spend Was Cut in Half and Losses Narrowed 40 Percent

NEW YORK (GenomeWeb News) — Accelr8 last week reported that third-quarter revenues were stable while R&D spending fell by half and losses narrowed 40 percent.
Total receipts for the three months ended April 30 increased to $22,700 from $19,800 year over year.
The company’s only revenue came from its OptiChem product line.
R&D spending was slashed to $247,500 from $490,000 year over year.
The company said net losses decreased to $477,000 from $789,000 in the year-ago period.
"The reduced losses reflect our planned transition from a product-engineering phase to an intensive testing phase using laboratory prototypes,” Accelr8 president David Howson said in a statement.
The company is testing an assay for methicillin-resistant Staphylococcus aureus infections, which are common in hospitals and be fatal.
Accelr8 said it had around $1.8 million in cash and cash equivalents as of April 30.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.